Drug Trial Radar · NCT07879885
An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
390
Planned (sponsor's estimate)
Start
Jul 31, 2025
Primary completion
Mar 1, 2027
Study completion Apr 1, 2027
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis
Conditions
- Moderate-to-severe Plaque Psoriasis
Interventions
HS-20137Biological
HS-20137 200 mg injection at weeks 0, 4 and 8
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse EventsTime frame: up to 20 weeks
- Changes From Baseline in Clinical Laboratory Test ResultsTime frame: Frame: up to 20 weeks
- Changes From Baseline in Physical Examination FindingsTime frame: up to 20 weeks
- Changes From Baseline in Vital SignsTime frame: up to 20 weeks
- Incidence of Clinically Significant Electrocardiogram (ECG) AbnormalitiesTime frame: up to 20 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijng, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.